Skip to content

Epistem Highlights Plucked Hair Biomarker Platform at Biomarkers 2024

We are delighted to announce Epistem's participation at Biomarkers 2024, London, from 29th February to 1st March 2024.

We are thrilled to share our innovative Plucked Hair Biomarker System – a pioneering platform enabling multiple serial sampling with minimal discomfort.

Epistem’s Plucked Hair Biomarker Platform stands out as a breakthrough in biomarker discovery, offering a non-invasive and easily accessible source for valuable biological information. Our platform empowers researchers and clinicians to glean crucial insights into disease mechanisms, treatment responses, and individual patient profiles through the analysis of plucked hair samples.

The hair biomarker platform can assist drug development programs in monitoring pharmacodynamic response to treatment, duration of drug effect, dose response, confirmation of mechanism of action and patient stratification.

We perform all hair biomarker studies in our GCLP-compliant histology and pharmacogenomics labs. Epistem has conducted GCLP-accredited clinical studies in support of drug development pipelines for a number of major pharmaceutical customers.

Stay tuned for updates from Biomarkers 2024 as we discuss the latest developments surrounding our Plucked Hair Biomarker Platform. We eagerly anticipate engaging with fellow professionals, exchanging insights, and exploring collaborative opportunities that will contribute to the advancement of healthcare and research.

To discuss your biomarker discovery needs, reach out to our attending delegate, Juan Menendez Gonzalez, or fill out our contact form here.


Biomarker FAQs

What are Pharmacodynamic Biomarkers?

Biomarkers in pharmacodynamics evaluate the biological reaction to a treatment procedure. They indicate whether a drug has engaged its intended target, provide evidence of the anticipated mechanism of action, help establish dose-response relationships, and allow monitoring of treatment efficacy over time.

What is the Biomarker Discovery phase?

The biomarker discovery phase refers to the initial stages of research aimed at identifying potential biomarkers that can be used for diagnostic, prognostic, or therapeutic purposes. and characterizing new potential biomarkers for a particular disease or biological process. The aim is to create strong initial data that shows the link between specific molecules and a disease or biological process. The most promising candidates then advance to further validation and clinical testing phases before potential regulatory approval as a biomarker.

What tissues are biomarkers typically sourced from?

The decision depends on several factors. These factors include the disease being studied, how the biomarker will be used, and how invasive the sampling procedure is.

  • Blood carries biomarkers from different parts of the body, making it a common source for testing. Serum and plasma biomarkers can provide systemic information.
  • Tissue biopsies allow direct insight of disease-specific biomarkers from the affected organ or tumour.
  • CSF is valuable for neurological diseases, as it provides a window into the central nervous system.

These tissues require invasive procedures to collect, whereas the Plucked Hair Biomarker Platform may provide less invasive options.


Event Description:

Biomarkers 2024 is Europe’s flagship event for Biomarker Research returns: engage with the latest trends transforming biomarker & translational research.